The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors

doi:10.1016/0046-8177(94)90056-6

Human Pathology

Volume 25, Issue 10, October 1994, Pages 968-981

https://doi.org/10.1016/0046-8177(94)90056-6 Get rights and content

Abstract

The evolution of sequential histological changes from normal cells through invasive cancer affords the cancer biologist the opportunity to identify separate molecular steps involved in cancer progression. As one studies the development of human carcinoma, it becomes apparent that multiple genetic alterations affecting both cellular proto-oncogenes and tumor suppressor genes are involved during the development and progression of both esophageal and gastric cancers. The different histological forms of both esophageal and gastric carcinomas as well as their differing etiologies result in the possibility that a spectrum of genetic changes is involved in different tumor types. p53 abnormalities occur frequently in tumors arising in both organs, and in both sites p53 abnormalities can be observed in precancerous lesions as well as in overt cancer. Subsequent abnormalities affecting other genes (eg, epithelial growth factor receptors [EGFRs]) potentially enhance the growth potential of tumors. This review focuses on abnormalities of oncogenes, tumor suppressor genes, and growth factors commonly found in cancers of the esophagus and stomach.

References (161)

GD Wu et al.
Sucrose-isomaltase gene expression in Barrett's esophagus and adenocarcinoma
Gastroenterology
(1993)
BD Westerveld et al.
Gastric proteases in Barrett's esophagus
Gastroenterology
(1987)
AP Naef et al.
Columnar-lined lower esophagus: An acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas
J Thorac Cardiovasc Surg
(1975)
HH Wang et al.
Comparative features of esophageal and gastric adenocarcinomas: Recent changes in type and frequency
Hum Pathol
(1986)
R Iggo et al.
Increased expression of mutant forms of p53 oncogene in primary lung cancer
Lancet
(1990)
S Ramel et al.
Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry
Gastroenterology
(1992)
CA Finlay et al.
The p53 proto-oncogene can act as a suppressor of transformation
Cell
(1989)
DP Lane
Worrying about p53
Current Biol
(1992)
B Vogelstein et al.
p53 Function and dysfunction
Cell
(1992)
L Hartwell
Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells
Cell
(1992)

Y Yin et al.

Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles

Cell

(1992)

F Imazeki et al.

p53 Gene mutations in gastric and esophageal cancers

Gastroenterology

(1992)

H Sasano et al.

Expression of p53 in human esophageal cancer: An immunohistochemical study with correlation to proliferating cell nuclear antigen expression

Hum Pathol

(1992)

M Younes et al.

p53 Protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study

Gastroenterology

(1993)

T Matozaki et al.

Missense mutations and a deletion of the p53 gene in human gastric cancer

Biochem Biophys Res Commun

(1992)

M Cross et al.

Growth factors in development, transformation, and tumorigenesis

Cell

(1991)

EB Leof et al.

Epidermal growth factor (EGF) and somatomedin C regulate G1 progression in competent $BALB c -3T3$ cells

Exp Cell Res

(1982)

S Cohen et al.

A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles

J Biol Chem

(1982)

R Derynck

Transforming growth factor α

Cell

(1988)

EP Sandgren et al.

Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast

Cell

(1990)

C Jhappan et al.

TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas

Cell

(1990)

MF Roussel et al.

Introduction of a human colony stimulating factor-1 gene into a mouse macrophage cell line induces CSF-1 independence but not tumorigenicity

Blood

(1988)

HC Pitot

The molecular biology of carcinogenesis

Cancer

(1993)

DP Lane

p53, Guardian of the genome

Nature

(1992)

JJ Wille et al.

Suppression of tumorigenicity by the cellcycle-dependent control of cellular differentiation and proliferation

Int J Cancer

(1986)

NE Dayne et al.

Esophagus

CL Carter et al.

Segregation analysis of esophageal cancer in 221 high-risk Chinese families

J Natl Cancer Inst

(1992)

RS Marger et al.

Carcinoma of the esophagus and tylosis: A lethal genetic combination

Cancer

(1993)

RB McConnell

The Genetics of Gastrointestinal Disorders. Oxford Monographs on Medical Genetics

P Ghadirian

Familial history of esophageal cancer

Cancer

(1985)

RM Jager et al.

Association of squamous carcinoma of the esophagus with a synchronous primary hepatocellular carcinoma

J Clin Gastroenterol

(1981)

JT Goodner et al.

Cancer of the esophagus. Its association with other primary cancers

Cancer

(1956)

AM Mandard et al.

Autopsy findings in 111 cases of esophageal cancer

Cancer

(1981)

PE Steiner

The etiology and histogenesis of carcinoma of the oesophagus

Cancer

(1956)

P Correa

A tumor model of gastric carcinogenesis

Cancer Res

(1988)

GN Stemmermann

The role of Helicobacter pylori in the etiology of gastric cancer

P Correa et al.

Pathology of gastric carcinoma in Japanese populations: Comparions between Miyagi Prefecture, Japan, and Hawaii

J Natl Cancer Inst

(1973)

C Toftgaard

Gastric cancer after peptic ulcer surgery: A historic prospective cohort investigation

Ann Surg

(1989)

HT Lynch et al.

Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review

Gastroenterology

(1990)

J Bartek et al.

Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro

Int J Cancer

(1979)

SJ Baker et al.

Chromosome 17 delections and p53 gene mutations in colorectal carcinomas

Science

(1989)

T Takahashi et al.

p53: A frequent target for genetic abnormalities in lung cancer

Science

(1989)

J Jankowski et al.

Oncogenes and onco-suppressor gene in adenocarcinoma of the esophagus

Gut

(1992)

HM Martin et al.

p53 Expression and prognosis in gastric carcinoma

Int J Cancer

(1992)

T Sano et al.

Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas

Cancer Res

(1991)

IB Runnebaum et al.

Mutations in p53 as potential molecular markers for human breast cancer

Y Yamada et al.

p53 Gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases

Cancer Res

(1991)

J Bartek et al.

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies

Oncogene

(1991)

WE Mercer et al.

Wild type human p53 is antiproliferative in SV40-transformed hamster cells

Oncogene

(1990)

SJ Kuerbitz et al.

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

Cited by (121)

Adenocarcinoma and Other Tumors of the Stomach
2010, Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print
Comparison of chromosomal aberrations between primary tumors and their synchronous lymph-node metastases in intestinal-type gastric carcinoma
2009, Pathology Research and Practice
Lymph-node metastasis is a main factor causing poor prognosis of patients with gastric cancer (GC). In order to determine the genes involved in lymph-node metastasis, we compared primary tumors with their synchronous lymph-node metastases for DNA sequence copy number aberrations (DSCNAs) in 20 patients diagnosed as having intestinal-type GC using comparative genomic hybridization (CGH). The results showed that some DSCNAs (gains at 8q, 13q, 5p, 7 and X, and losses at 1p, 17p, 19, 21q and 22q) were frequently found in both primary tumors and their metastases. However, metastases often contained DSCNAs that were not found in corresponding primary tumors, and gain at 20q12–13 and losses at 21qcen-21, 4q and 14q22-ter were significantly more frequently observed in metastatic lesions than in their primary tumors (10:2, 9:0, 6:0, and 7:0 between metastases and corresponding primary tumors, respectively). Our data indicate that gain at 20q12–13 and losses at 21qcen-21, 4q, and 14q22-ter are involved in lymph-node metastases, and that these chromosomal regions may contain the genes related to lymph-node metastases in intestinal-type GC.
Gastric epithelial dysplasia: The Western perspective
2008, Digestive and Liver Disease
Citation Excerpt :
APC gene is mutated in 20–76% of gastric adenomas and flat dysplasias and nuclear p53 staining may be seen in about one third of these cases [63–68]. TP53 mutations have also been described in H. pylori gastritis and in foci of intestinal metaplasia suggesting these are early events in gastric carcinogenesis [69–81]. Microsatellite instability (MSI) may occur in about 21% of gastric adenomas, [65,71,76,82–87] while the exact role of KRAS oncogene mutation in gastric neoplasia is debatable [65,66,69,82,88,89].
The need for early diagnosis of gastric cancer is emphasized by the fact that gastric cancer remains the second most common cause of cancer related deaths worldwide. The aggressive surveillance and definite therapy for low and high-grade dysplasia, which can be achieved endoscopic means, remains the cornerstone of clinical management.
Although the precursor status of dysplasia is not contested, its classification is controversial and fraught with marked inter-observer variations. Most cases of gastric dysplasia have an “intestinal” phenotype referred to as adenomatous dysplasia. Hyperplastic (type II dysplasia) is another less common variant.
The progression of dysplasia to carcinoma is paralleled by a stepwise accumulation of multiple, but yet uncertain, genetic abnormalities. There are no immunohistochemical or molecular assays that can stratify with certainty the risk of progression to cancer.
Given the low rate of transformation of low-grade dysplasia, annual endoscopic surveillance with re-biopsy is advocated. A diagnosis of indefinite for dysplasia should also prompt endoscopic surveillance.
A diagnosis of high-grade dysplasia is more ominous, since it progress to cancer in most cases. However, the novel imaging and endoscopic modalities have modified management strategies with mucosal lesions amenable to endoscopic resection, while surgical resection is reserved to invasive adenocarcinoma with submucosal invasion.
Gastric Preneoplastic Lesions and Epithelial Dysplasia
2007, Gastroenterology Clinics of North America
Citation Excerpt :
Immunohistochemical studies have shown p53 nuclear staining in about one third of cases of gastric dysplasias or adenomas [110–118], usually, but not invariably, limited to areas of high-grade dysplasia [112,115,116,118,119]. Interestingly, p53 mutations also have been detected (by immunohistochemistry or molecular techniques) in H pylori gastritis and intestinal metaplasia (approximately 30%), indicating that p53 alterations may be an early event in gastric carcinogenesis [120–122]. The role of K-ras mutations in gastric adenomas is debatable.
Microsatellite analysis of the APC gene and immunoexpression of E-cadherin, catenin, and tubulin in esophageal squamous cell carcinoma
2006, Human Pathology
The histological features that accompany the development and progression of solid tumors are known to be controlled by a distinct cascade of molecular events. One such event is the inactivation of tumor suppressor genes, such as the adenomatous polyposis coli (APC) gene. Disruption of the cadherin-catenin cell adhesion complex also plays a role in the initial steps of cancer invasion and metastasis whereas alterations in cell structural molecules, such as tubulin, may contribute to the cancer phenotype. The understanding of the status of these molecules in ESSC may provide novel markers that could impact on management of the disease. The present study examined alterations in the microsatellite sequence of the APC gene via fluorescent-based polymerase chain reaction in 100 cases of primary esophageal squamous cell carcinoma. In addition, the expression of E-cadherin, α- and β-catenin, and α- and β-tubulin was analyzed using immunohistochemistry. These data were then statistically compared with each other as well as the relevant clinicopathologic data. Although the APC markers (D5S210, D5S346, D5S299, and D5S82) tested did show an overall high frequency of allelic imbalance/loss of heterozygosity (62.48%) and microsatellite instability (41.27%), they did not show prognostic significance in the study cohort and were not correlated with the immunohistochemical data. The tubulin proteins showed no significant change in expression in the tumor tissue The decreased immunoreactivity of E-cadherin was statistically correlated with the presence of lymph node metastases (P = .0180). Although α- and β-catenin as well as E-cadherin showed no direct prognostic value, E-cadherin may warrant further investigation as an indirect prognostic indicator by allowing more accurate prediction of lymph node metastases.
Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: Bacterial and host factors responsible for altered growth signaling
2004, Gene
Gastric cancer remains the second most common cause of cancer-related mortality worldwide. The single most common cause of gastric cancer is chronic infection with the gram-negative microaerophilic spiral bacterium: Helicobacter pylori. Recent advances in this field have identified host factors which predispose to gastric cancer formation via modulation of the host immune response. In addition, recent work has explored bacterial virulence factors which may directly cause tissue damage, and lead to gastric carcinogenesis, as well as factors responsible for enhanced immune response. Environmental factors, long associated with a predilection for gastric cancer, are recognized as modifiers of key growth signalling pathways within the gastric mucosa and as such lead to growth alterations. This review focuses on exploring new advances in our understanding of bacterial factors, host genetic polymorphisms and the interaction between the bacterium and host at the level of the immune response and the regulation of proliferative and apoptotic signal transduction cascades. Modulation of the pivotal balance between cell growth and cell death leads to the formation of gastric adenocarcinoma.

View all citing articles on Scopus

¹: S.C.H., M.A.M., and C.M.F.-P. are supported in part by the National Cancer Institute, Bethesda, MD, grant no. 5U10CA32102. A.N. is supported in part by a Clinical Oncology Fellowship of the Ohio Division of the American Cancer Society, Dublin, OH.

View full text

The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors

Abstract

Gastroenterology

Gastroenterology

J Thorac Cardiovasc Surg

Hum Pathol

Lancet

Gastroenterology

Cell

Current Biol

Cell

Cell

Cell

Gastroenterology

Hum Pathol

Gastroenterology

Biochem Biophys Res Commun

Cell

Exp Cell Res

J Biol Chem

Cell

Cell

Cell

Blood

The molecular biology of carcinogenesis

Cancer

p53, Guardian of the genome

Nature

Suppression of tumorigenicity by the cellcycle-dependent control of cellular differentiation and proliferation

Int J Cancer

Esophagus

Segregation analysis of esophageal cancer in 221 high-risk Chinese families

J Natl Cancer Inst

Carcinoma of the esophagus and tylosis: A lethal genetic combination

Cancer

The Genetics of Gastrointestinal Disorders. Oxford Monographs on Medical Genetics

Familial history of esophageal cancer

Cancer

Association of squamous carcinoma of the esophagus with a synchronous primary hepatocellular carcinoma

J Clin Gastroenterol

Cancer of the esophagus. Its association with other primary cancers

Cancer

Autopsy findings in 111 cases of esophageal cancer

Cancer

The etiology and histogenesis of carcinoma of the oesophagus

Cancer

A tumor model of gastric carcinogenesis

Cancer Res

The role of Helicobacter pylori in the etiology of gastric cancer

Pathology of gastric carcinoma in Japanese populations: Comparions between Miyagi Prefecture, Japan, and Hawaii

J Natl Cancer Inst

Gastric cancer after peptic ulcer surgery: A historic prospective cohort investigation

Ann Surg

Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review

Gastroenterology

Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro

Int J Cancer

Chromosome 17 delections and p53 gene mutations in colorectal carcinomas

Science

p53: A frequent target for genetic abnormalities in lung cancer

Science

Oncogenes and onco-suppressor gene in adenocarcinoma of the esophagus

Gut

p53 Expression and prognosis in gastric carcinoma

Int J Cancer

Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas

Cancer Res

Mutations in p53 as potential molecular markers for human breast cancer

p53 Gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases

Cancer Res

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies

Oncogene

Wild type human p53 is antiproliferative in SV40-transformed hamster cells

Oncogene

Wild-type p53 is a cell cycle checkpoint determinant following irradiation